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A notable trend in the Society for the Study of Behavioural Phenotypes Scientific Symposium 
abstracts that are published annually in this special edition, is the increase in the number of 
papers that refer explicitly to intervention for intellectual disability at a level other than 
behaviour change. This trend reflects and is driven by the greater clarity of understanding of the 
pathways from genetic disorder to central nervous system development, to cognitive 
endophenotype, to behaviour and the interaction between behaviour and the immediate and 
remote environment. The study of pathways to behavioural phenotypes associated with genetic 
disorders has influenced the conceptualisation of intellectual disability by attempting to account 
for behavioural variability by demonstrating the effects of individual cognitive difference and 
developmental trajectories alongside environmental influences. This redresses the balance within 
biopsychosocial models of behavioural outcome in intellectual disability and emphasises the 
need for models that: 1) have empirical support, 2) identify the pathways from biological 
disorder to behaviour, 3) have multiple levels of explanation and 4) are set in a developmental 
context.  
The invited review in this edition by Moore and George (2011) provides a way of describing 
these models that helps demonstrate complexity and indicates different points of intervention. By 
using the methods suggested by Moore and George, it is possible to make specific predictions 
about the immediate and longer term effects of intervention. The concepts and levels of 
explanation made explicit by this approach are to some extent evident in many of the studies 
described in the published abstracts. Cornish and Hocking (2011) suggest an influence on 
inhibition and working memory of the number of CGG repeats in males with the Fragile X 
premutation. Similarly, Wong et al. (2011) suggest that TSC1 and TSC2 mutations lead to 
different cognitive outcomes in Tuberous Sclerosis Complex. Studies like these are providing the 
evidence needed to complete the models that Moore and George are promoting. 
As these multilevel models evolve and become more refined so we see evidence of targeted 
intervention with clinical trials currently being run in many centres for disorders such as 
Tuberous Sclerosis Complex, Fragile X, Angelman and Rett syndrome. Some of these trials are 
promising and are in a variety of stages of development from Phase 1-3 trials. Tuberous 
Sclerosis, for example, is now understood to involve the TSC complex with resultant decreased 
3 
Behavioural phenotypes 
 
activation of mTOR signaling, part of the growth factor signaling. Thus, mutations in TSC1 and 
TSC2 involve loss of control of cell growth and cell division. Targeted therapies including 
rapamicin and everolimus have shown interesting effects. Rapamicin has been shown to rescue 
learning and memory deficits in mouse models (Ehninger and Silva, 2011) and Everolimus has 
been approved in some countries for use in Subependymal Giant Cell Astrocytoma (SEGA) after 
an open label study of 28 patients (children and adults) with SEGAs (Krueger et al., 2010). 
Positive effects were seen in size of the SEGA, facial angiofibromas and in seizures. However, 
no changes were observed in neuropsychological outcome. The changes seen in animal models 
may be directly related to learning and memory and also to commonly observed autistic like 
behaviours in this group. Common links to mTor pathways in animal models are present in 
Fragile X and neurofibromatosis, both of which are disorders with common presentations of 
autistic phenotypes and epilepsy. This suggests that this pathway may be implicated in 
developmental aspects of these phenotypes. 
Trials of medication targeted at modifying anxiety, cognitive impairments and autistic like 
features for those with Fragile X syndrome are currently underway. The study by Winarni et al., 
(2011) in this edition, suggests Sertraline may influence language beneficially in young children 
with Fragile X syndrome, although the study warrants replication using a more robust design. A 
better understanding of the molecular pathways in Fragile X syndrome has resulted in the 
development of a number of therapeutic strategies. Reduced expression of the Fragile X Mental 
Retardation Protein (FMRP), an RNA binding protein that negatively regulates protein synthesis, 
has a downstream effect increasing activity of mGluR5.  Fenobam, STX 107, AFQ56, 
RO4917523 (mGluR5 antagonists) are currently being trialed in phase 2 and 3 studies 
internationally. Other trials are aimed at treating upstream or downstream of the mGluR5 
complex with STX209 (Arbaclofen) being trialed as a stimulator of the GABA(B) receptors with 
evidence of decreased anxiety and hyperactivity (Krueger and Bear, 2011). Minocycline has also 
been used resulting in better dendritic spine growth in animal studies. Lithium which targets 
multiple intracellular pathways related to mGluR5 and Fragile X has also been trialed in pilot 
studies with some positive effects. Results of larger scale randomised blinded trials are eagerly 
anticipated. Importantly it may be that these findings may extend to wider populations of 
children with dysregulation of mGluR5. 
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Models of the neural development in Rett syndrome emphasise mutations in the gene coding for 
MECP2 which is critical for the growth of neural spines. Mutations in the CDLK5 gene have 
also been found in girls with a phenotype overlapping that of classical Rett syndrome. In 
particular an early seizure onset phenotype is associated with mutations in the CDLK5 gene. 
These pathways overlap and present with a similar phenotype (Mari et al., 2005, Weaving et al 
2004). L Carnitine has been studied and shown positive effects in hand apraxia and increased 
heart rate variability. Animal models have suggested that IGF-1 can ameliorate this effect and 
current trials are underway testing this hypothesis in girls with Rett syndrome. Interest has been 
in read-through effects on the nonsense mutations seen in MECP2 by aminoglycosides, however 
the side effects have been problematic. Newer agents however are being evaluated and may be 
more clinically tolerable (Brendel et al., 2011). Other studies evaluating Dextromethorphan 
(NMDA/Glutamate receptor blocker) are also underway. The studies evaluating the role of 
methylation in this group have not shown a significant effect in objective clinical measures but 
are small (Glaze, Percy and Motil 2009). Finally, in this edition, the results of the study by 
Rawas et al., (2011) suggest a 5-HT1-A agonist might ameliorate some of the severe breathing 
dysrhythmias seen in Rett syndrome. 
All of these disorders are rare and funding at national and international levels is often directed at 
more common disorders with a stronger lobby. It is not uncommon for Research Councils in the 
UK to reject funding applications on the basis of the rarity of a disorder. However, it could be 
argued that common behavioural phenotypes are likely to share common pathways and thus 
there is much to learn from specific syndromes. It is also likely that a multidisciplinary approach 
with clinicians and basic scientists working together will lead to translation of complex 
molecular information into understanding and therapies that are likely to benefit not only those 
with specific syndromes but also those with similar phenotypes. In this edition Holland (2011) 
notes the importance of behavioural phenotype research to the Foresight review conducted in the 
UK that was designed to map out the future research landscape and it is evident that the study of 
individual genetic disorders could play a critical strategic role in improving the understanding of 
mental health and behavioural difference and disorder in people with intellectual disability. Clear 
understanding of the behavioural attributes and differences between different groups are the basis 
to the model building that will make explicit similarities and differences in pathways that then 
5 
Behavioural phenotypes 
 
suggest shared or different points of intervention across groups. It is these shared and different 
pathways that will be discussed and debated at this year’s SSBP meeting in Brisbane. 
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